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ABSTRACT Senescent cell antigen, a polypeptide that ap-
pears on the surface of senescent and damaged cells, has been
shown to be derived from band 3. In the present study, the
relationship between the as yet unidentified glucose transport-
er and senescent cell antigen is examined. Since cytochalasin B
is a specific and potent competitive inhibitor of glucose trans-
port in human erythrocytes, the glucose transport carrier was
isolated by affinity chromatography on cytochalasin B-Sepha-
rose 4B columns and eluted with D-glucose. This purification
procedure is both a method of isolation and a functional assay
for the glucose transporter. Purified glucose transporter gave
a sharp, single band at Mr =60,000 when analyzed by NaDod-
SO4/PAGE. Glucose transporter was identified in erythrocyte
membranes by the immunoblotting technique, using both anti-
bodies raised against purified glucose transporter and anti-
idiotypic antibodies. Two-dimensional peptide mapping re-
vealed substantial peptide homology between glucose trans-
porter and senescent cell antigen. In addition, the glucose
transporter shared peptide homology with band 3 and its de-
fined proteolytic fragments located toward the carboxyl termi-
nus of band 3. Peptide homology between glucose transporter
and the Mr =41,000 cytoplasmic segment of band 3 that con-
tains the amino terminus could not be demonstrated. Thus,
glucose transporter appears to be part of or derived from band
3, and to share substantial peptide homology with senescent
cell antigen.
Senescent cell antigen is a glycosylated 4.5-region polypep-
tide that appears on the surface of senescent and damaged
erythrocytes (1-14). [The "4.5 region" on NaDodSO4/poly-
acrylamide gels contains polypeptides migrating between
band 4.2 and band 5 (actin).] It is recognized by the antigen-
binding (Fab) region (3, 4) of a specific IgG autoantibody in
serum which attaches to it and initiates the removal of cells
by macrophages (5). Although the senescent cell antigen was
first demonstrated on the surface of senescent human eryth-
rocytes (1, 2), it has since been demonstrated on the surface
of lymphocytes, polymorphonuclear leukocytes, platelets,
embryonic kidney cells, and adult liver cells (4). A molecule
immunologically related to band 3, the molecule from which
senescent cell antigen is derived, has been observed on all
cells examined (15).
Senescent cell antigen has been "mapped" on the band 3
molecule by using topographically defined fragments of band
3 (16). Both binding of IgG eluted from senescent erythro-
cytes ("senescent cell IgG") to defined proteolytic fragments
of band 3 in immunoblots and two-dimensional peptide map-
ping localized senescent cell antigen to a region on the extra-
cellular (outer-surface) portion of band 3 that includes most
of the -38-kDa carboxyl-terminal segment and about 30% of
the "17-kDa anion-transport region.
It was postulated that senescent cell antigen and glucose
transporter were breakdown products of band 3 that were
physiologically related (6). Both proteins migrate in the
broad, uncharacterized 4.5 region of NaDodSO4/polyacryla-
mide gels (4, 17). At least four polypeptides in this region
stain with antibodies to band 3 (9, 10, 16). One of these poly-
peptides, the senescent cell antigen, appears to be derived
from band 3 (6, 9, 10, 16). Band 3 is the major anion-trans-
port polypeptide of the erythrocyte membrane, and, in addi-
tion, appears to be the binding site for the glycolytic en-
zymes glyceraldehyde-3-phosphate dehydrogenase (18), al-
dolase (19), and phosphofructokinase (20). In the present
study, the relationship between the as yet unidentified glu-
cose transporter that supplies energy to cells and the senes-
cent cell antigen that signals the termination of a cell's life
(1-14) is examined.
MATERIALS AND METHODS
Isolation of IgG from Senescent Erythrocytes and of Senes-
cent-Cell Antigen. Senescent cell IgG was isolated as previ-
ously described (3, 4). Senescent cell antigen was isolated by
affinity chromatography with senescent cell IgG conjugated
to Sepharose 4B as described (4, 6).
Isolation of the Glucose Transporter. Since cytochalasin B
is a specific and potent competitive inhibitor of D-glucose
transport in human erythrocytes (21, 22), the glucose trans-
port carrier was isolated by affinity chromatography on cy-
tochalasin B-Sepharose 4B columns and eluted with D-glu-
cose. This purification procedure is both a method of isola-
tion and a functional assay for the glucose transporter (17,
23). Cytochalasin B (Calbiochem) was dissolved in dimethyl
sulfoxide or absolute ethanol and conjugated to Sepharose
4B. Erythrocyte ghosts were prepared as described previ-
ously (10, 14, 15). NaOH-stripped membranes were solubil-
ized with 0.1 M Tris/HCl, pH 8.0, containing 0.1 M NaCl, 1
mM EDTA, 1 mM EGTA, 1 mM diisopropyl fluorophos-
phate, and 0.1% NaDodSO4 (10, 14, 15). After centrifuga-
tion, the supernatant was incubated overnight at 4°C with
cytochalasin B-Sepharose. The Sepharose was removed by
centrifugation and washed five times with 5 mM phosphate
buffer, pH 7.4, containing 1 mM EDTA, 1 mM EGTA, and 5
mM diisopropyl fluorophosphate. It was poured into a col-
umn and washed with 10 volumes of the same buffer in
which the membranes were solubilized except that it con-
tained 0.02% rather than 0.1% NaDodSO4. After washing
with 2 volumes of 1.0 M NaCl and 400 volumes of 0.15 M
NaCl, bound material was eluted with 0.5 M D-glucose.
Preparation of Antibodies to the Glucose Transporter. Glu-
cose transporter was isolated by affinity chromatography
with cytochalasin B. While still bound to the column, the
transporter was delipidated using water/ethanol/ether
(1:1:4, vol/vol) and chloroform/methanol (2:1, vol/vol). The
delipidated glucose transporter was specifically eluted from
the affinity column with D-glucose and injected into rabbits,
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using a biweekly injection schedule. Rabbits were bled 3 out
of 4 weeks starting 1 week after the third injection. The IgG
fraction was isolated by affinity chromatography on protein
A-Sepharose.
Anti-idiotypic antibodies to the glucose transporter were
prepared according to the method of Wassermann et al. (24).
Briefly, antibodies were prepared against glucose by conju-
gating glucosamine to Sepharose 4B and injecting rabbits bi-
weekly with the conjugate. Glucosamine rather than glucose
was used because an amino group was necessary for cou-
pling. After the third injection, glucosamine conjugated to
bovine serum albumin as a carrier was injected on a biweek-
ly schedule. The antisera were pooled, and antibodies to glu-
cose were isolated by affinity chromatography on glucosa-
mine-Sepharose 4B columns. Antibodies to glucose were
eluted with glucose at pH 7.4. These antibodies then were
injected into other rabbits to produce anti-idiotypic antibod-
ies. The anti-idiotypic antibody rabbits were bled and the
sera were adsorbed with bovine serum albumin and erythro-
cyte peripheral membrane proteins conjugated to Sepharose.
The IgG fraction was isolated by affinity chromatography on
protein A-Sepharose.
Antibodies to Band 3. Antibodies to purified band 3 were
prepared in rabbits as described (9, 10, 14, 15).
Enzymatic Treatment of Erythrocytes. Fragments are re-
ferred to by the nomenclature of Steck et al. (25, 26).
Washed erythrocytes were incubated overnight at 240C in
phosphate-buffered saline containing 1 mM ATP and a-chy-
motrypsin (200 gg/ml). a-Chymotrypsin specifically digests
band 3, yielding fragments of Mr -55,000 and =z38,000 (25,
26), designated CH-55 and CH-38, respectively (25). The
CH-55 fragment appears to have a Mr closer to 60,000 in our
experiments. Digestion was terminated by the addition of 5
mM diisopropyl fluorophosphate. Cells were washed four
times with phosphate-buffered saline and processed in the
same manner as described for intact erythrocytes.
The Mr =41,000 cytoplasmic segment (TR-41) of band 3
was produced by mild trypsin digestion of spectrin-depleted,
NaOH-stripped inverted vesicles (27).
The Mr -19,000 intramembranous fragment (CH-TR-19),
which includes CH-17, was produced by a-chymotrypsin
treatment of intact red cells followed by treatment of spec-
trin-depleted inverted vesicles with trypsin (28). Proteolysis
was terminated by the addition of 5 mM diisopropyl fluoro-
phosphate. Membranes were washed twice with 5 mM sodi-
um phosphate, pH 8.0/1 mM EDTA/1 mM EGTA/1 mM
diisopropyl fluorophosphate.
NaDodSO4/PAGE. Proteins were analyzed in three differ-
ent polyacrylamide gel systems: 7% gels and 6-25% and 12-
25% linear gradient gels. The discontinuous buffer system of
Laemmli was used (29). Mrs given are approximate and can
vary 5-10% depending on the PAGE system employed.
Immunostaining of Membrane Proteins. Immunoautoradi-
ography was carried out either by the immunoblotting tech-
nique of Towbin et al. (30) with the modifications described
previously (9, 10, 14-16) or by the gel-overlay method (10).
Two-Dimensional Peptide Mapping. Two-dimensional pep-
tide maps were obtained by the method of Elder et al. (31),
using the modifications described previously (16). Chro-
matograms were dried and exposed to Kodak X-Omat film in
Dupont cassettes with Cronex Lightning Plus intensifying
screens for 1-3 days at -80°C.
RESULTS
Identification of the Glucose Transporter by Using Antibod-
ies Prepared Against It. Glucose transporter purified by af-
finity chromatography has a Mr =60,000 as determined by
NaDodSO4/PAGE (Fig. 1). Rabbit antibodies prepared
against purified glucose transporter gave a very strong reac-
tion with a polypeptide of Mr -78,000 (between bands 4.1
and 4.2) in NaDodSO4/polyacrylamide gels of erythrocyte
membranes. In addition, antibodies against purified glucose
transporter reacted with band 3, minor bands and one major
band in the 4.5 region, and polypeptides of Mr -40,000,
38,000, and 18,000 in immunoblots of erythrocyte mem-
branes (Fig. 2, lane B). Antibodies to band 3 reacted with
these same polypeptides, suggesting that they are immuno-
logically related to band 3 (Fig. 2, lane A).
Identification of the Glucose Transporter Using Anti-Idio-
typic Antibodies. According to the anti-idiotypic network
theory of Jerne (32), injection of an antigen elicits antibodies
to the antigen and, in addition, anti-idiotypic antibodies di-
rected at the antigen-combining site (Fab hypervariable re-
gion) of the antigen-specific antibodies. It has been shown
that production of antigen-specific antibodies against a lig-
and of a receptor results in anti-idiotypic antibodies that bind
to the receptor itself (24, 33, 34). For example, immunization
with insulin results in the production not only of antibodies
to insulin (idiotypes) but also of antibodies that recognize the
insulin receptor (anti-idiotypes) which are produced against
the anti-insulin antibodies (35, 36). The anti-idiotypes steri-
cally fit the combining sites of the idiotypes. Thus, the anti-
idiotype appears to have a three-dimensional configuration
similar to that of the ligand antigen (32, 35). Use of anti-idio-
types bypasses the requirement for a purified membrane
molecule, since the initial antibody is made against the ligand
and not the receptor (33).
Anti-idiotypic antibodies reacted with band 3, one poly-
peptide of apparent Mr =78,000, and one polypeptide (Mr
-45,000) in the 4.5 region in NaDodSO4/PAGE (Fig. 2, lane
C). In addition, anti-idiotypic antibodies reacted with two
faint bands in the 4.5 region (Mr =67,000 and 58,000). Anti-
bodies to band 3 reacted with these same polypeptides (Fig.
A 13 C
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FIG. 1. NaDodSO4/6-25% PAGE of affinity chromatography-
purified glucose transporter (lane A) and senescent cell antigen (lane
B) and of erythrocyte membrane proteins (lane C). Band designa-
tions are at right.
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FIG. 2. Immunoblots of erythrocyte membrane proteins incubat-
ed with antibodies to band 3 (lane A), antibodies against purified
glucose transporter (lane B), anti-idiotypic antibodies directed
against the glucose receptor (lane C), and IgG eluted from senescent
cells (lane D). Erythrocyte membrane proteins were separated on
NaDodSO4/12-25% polyacrylamide gels.
2, lane A). IgG eluted from senescent cells reacted with band
3, a 4.5 region polypeptide with a lower Mr than that of the
glucose transporter (Mr -67,000), a polypeptide of Mr
=45,000, and a polypeptide of Mr -18,000 (Fig. 2, lane D).
Specific antibodies to band 3 also react with these polypep-
tides (Fig. 2, lane A).
Peptide Mapping Analysis of Band 3, Glucose Transporter,
and Senescent Cell Antigen. Immunological data suggest that
band 3 and glucose transporter are related. Therefore, com-
parative two-dimensional peptide mapping was performed to
determine the extent of homology between the two polypep-
tides. Peptide homology between glucose transporter and se-
nescent cell antigen was also evaluated because senescent
cell antigen not only is derived from band 3 but also has been
localized on the band 3 molecule. Comparative analysis of
peptide maps (Fig. 3) revealed that glucose transporter (Fig.
3B) shares peptide homology with band 3 (Fig. 3A), the CH-
38 carboxyl-terminal segment (Fig. 3C), and the CH-TR-19
anion-transport segment (Fig. 3F). The proportion of pep-
tides in each map that appear in glucose transporter is as
follows: band 3, 39-43% (27 peptides appear in glucose
transporter/63-69 peptides in the map of band 3); CH-38,
63% (26/41); CH-TR-19, 67% (22/33); CH-55, 20% (10/50);
TR-41, 3-5% (1 or possibly 2/40). The peptides present in
the glucose transporter are present in the peptide map of
band 3. Glucose transporter has 7-10 peptides that do not
appear in CH-38 and 6 peptides that do not appear in CH-
TR-19. However, all except 2 of the peptides in glucose
transporter appear in the combined maps of CH-38 and CH-
TR-19 as determined by superimposing the autoradiographs.
These 2 glucose-transporter peptides that are not present in
CH-38 combined with CH-TR-19 may be contributed by TR-
41. Alternatively, they could result from technical factors
discussed previously (16). For example, degradation of a
polypeptide can produce an additional peptide at each end of
a fragment where it was cleaved from band 3. Senescent cell
antigen contains fewer peptides than glucose transporter,
but all of the peptides present in the map of senescent cell
antigen are present in the map of glucose transporter. Thus,
glucose transporter (Fig. 4A) shares substantial peptide ho-
mology with senescent cell antigen (Fig. 4B), although the
two maps are not identical.
DISCUSSION
Both the immunological and peptide mapping data indicate
that glucose transporter is related to band 3. Glucose trans-
porter appears to contain band 3 segments CH-38 and CH-17
and possibly several additional peptides. Thus, the calculat-
ed Mr of glucose transporter based on peptide mapping data
is 255,000. Purified glucose transporter migrates at Mr
-60,000 in PAGE, which is consistent with the peptide map-
ping data. However, both antibodies prepared against puri-
fied glucose transporter and anti-idiotypic antibodies to the
glucose transporter react with a polypeptide of Mr =78,000
in erythrocyte membranes. The most probable explanation
for the difference in apparent Mrs between purified glucose
transporter (Mr -60,000) and the polypeptide labeled with
antibodies in erythrocyte membranes is that degradation oc-
curred during removal from membranes or during isolation
procedures. It should be noted that both antibodies to glu-
cose transporter and anti-idiotypic antibodies reacted with
lower Mr polypeptides as well as the Mr -78,000 polypeptide
in erythrocyte membranes. It is also possible that carbohy-
drates, glycolipids, or other membrane components could be
associated with glucose transporter in membranes, thus in-
creasing its apparent Mr, but that these associated compo-
nents are removed or reduced during purification.
Glucose transporter is probably derived from or part of the
band 3 molecule. However, mapping the peptides of glucose
transporter to specific segments of band 3 is an approxima-
tion for reasons discussed elsewhere (16). Furthermore, if
band 3 degradation occurs in situ, there is no reason to ex-
pect that in situ degradation would produce the same band 3
cleavage that we produce in vitro with enzymes.
Both glucose transporter and senescent cell antigen ap-
pear to be related to each other based on immunological and
peptide mapping data. Both polypeptides appear to be locat-
ed on segments toward the carboxyl rather than the amino
terminus of band 3. Although senescent cell antigen appears
to contain CH-38 and part of the CH-17 anion-transport seg-
ment of band 3 (16), glucose transporter appears to contain
CH-38 and most of CH-17. Thus, glucose transporter ap-
pears to be larger than senescent cell antigen by peptide
mapping analysis as well as antibody staining.
Neither purified senescent cell antigen nor glucose trans-
porter appear to contain the cytoplasmic segment of band 3.
It is possible that the cytoplasmic segment of band 3 (TR-41)
behaves like a cytoskeletal protein with predominantly
structural functions. It extends into the cytoplasm and ap-
pears to be the binding site for glyceraldehyde-3-phosphate
dehydrogenase (37), aldolase (38), and band 2.1 (39). The cy-
toplasmic segment may also be more sensitive to proteolysis
in vivo and/or in vitro. If this were the case, TR-41 could be
degraded even though protease inhibitors are present
throughout all procedures. Since TR-41 is not anchored in
the membrane, it may be lost during the processing of mem-
branes. The observation that breakdown products of band 3
increase with cellular aging suggests that degradation occurs
in vivo (16).
The glucose transporter was isolated by affinity chroma-
tography with cytochalasin B, a specific and potent competi-
tive inhibitor of D-glucose transport (21, 22), and eluted with
D-glucose. Thus, the method of isolation and purification-
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FIG. 3. Two-dimensional peptide maps of band 3, proteolytic products of band 3, and glucose transporter. (A) Band 3. (B) Glucose trans-
porter. (C) CH-38. (D) CH-55. (E) TR-41. (F) CH-TR-19. This experiment was repeated 11 times on two different samples of glucose transport-
er and 4-5 different samples of the other polypeptides. Directions of electrophoresis (E) and TLC are shown, as is the origin (0) in D.
namely, cytochalasin B binding-is a functional assay that
has been used to determine the presence of glucose trans-
porter following other methods of isolation and/or enrich-
ment (17, 23, 40). Antibodies prepared against the affinity-
purified glucose transporter give a strong reaction with a Mr
-78,000 polypeptide, a weaker reaction with band 3, and re-
act with faint bands in the 4.5 region and polypeptides at Mr
-38,000 and -18,000. In contrast, anti-idiotypic antibodies,
which bypass the requirement for a purified receptor (33),
bind to band 3 and its Mr 78,000 and 45,000 breakdown prod-
ucts. Anti-idiotypic antibody staining of band 3 is at least as
A
SF
strong as staining of the Mr 78,000 polypeptide. The differ-
ences in staining patterns between the antibodies to purified
glucose transporter and the anti-idiotypic antibodies to glu-
cose transporter are probably due to several factors. First,
even though glucose transporter is treated to remove lipids,
binding of associated lipid is reduced but not abolished by
the procedures employed. Second, anti-idiotypic antibodies
recognize the active site of the glucose transporter. There-
fore, if the active site for glucose transport is a protein, then
anti-idiotypes would "recognize" the protein and not associ-
ated carbohydrates or lipids. Polyclonal antibodies against
B
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FIG. 4. Two-dimensional peptide maps of glucose transporter (A) and senescent cell antigen (B).
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purified glucose transporter, on the other hand, would rec-
ognize any associated components and bind to them regard-
less of the molecule on which they appear. Since a number of
glycoproteins may, for example, have similar sugar groups
attached, the antibodies to purified glucose transporter may
react with non-transport proteins on the basis of carbohy-
drate content rather than active-site configuration.
Early studies on the identification of the glucose trans-
porter using affinity labeling or cytochalasin B binding sug-
gested that glucose transport activity was attributable to
band 3 (41, 42). This view was later supplanted by evidence
indicating that an integral membrane glycoprotein of Mr
45,000-55,000 was probably the glucose transporter (17, 23).
In the latter case, the glucose transporter was identified by
[3H]cytochalasin B binding to Triton X-100 extracts of eryth-
rocyte proteins that were retarded on ion-exchange columns.
Elution of the glucose transporter in these experiments did
not require a pH or ion shift, and yielded a heterogeneous
mixture which gave broad bands throughout the gels from
the band 3 region to the tracking dye front (23). Antibodies
prepared against glucose transporter obtained in this manner
reacted with polypeptides of Mr 40,000-80,000 (23). A re-
view of the PAGE data presented by Sogin and Hinkle (23)
reveals that the trailing edge of antibody binding to glucose
transporter, both in isolated preparations and in membranes,
is in the band 3 (Mr ==100,000) region while the leading edge
is in the band 6 region (Mr -35,000). Zoccoli et al. (43) found
that the Mr of the glucose transporter was 225,000 by using
gel filtration and sucrose gradient centrifugation. They sug-
gested that the solubilized cytochalasin B-binding complex
contains one or two polypeptide chains (43), possibly dimers
or aggregates of band 3.
The results presented here, which indicate that purified
glucose transporter is structurally related to band 3, and that
antibodies against affinity-purified glucose transporter react
with band 3, a Mr -78,000 polypeptide, faint bands in the 4.5
region, and lower Mr polypeptides, explain and reconcile the
apparently disparate results obtained by other groups.
Yu and Steck (44) have suggested previously the possibili-
ty that band 3 itself is a set of closely related polypeptides
that have several transport functions. The data presented
here are consistent with this hypothesis and suggest that
band 3 may be responsible for glucose as well as anion trans-
port. In addition, the multifunctional band 3 molecule ap-
pears to be the origin for the senescent cell antigen (9-11,
16), a molecule whose appearance initiates a sequence of im-
munological events resulting in removal of "marked" cells
(1-5).
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